These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 1970478)

  • 1. [Individualized sulfasalazine treatment of ulcerative colitis and monitoring of patient compliance by determining sulfapyridine serum concentration].
    Klugmann HJ; Giehler B; Lohmann D; Schiedewitz W
    Gastroenterol J; 1990; 49(4):160-4. PubMed ID: 1970478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Ulcerative colitis in children. Levels of salicylazosulfapyridine and sulfapyridine during treatment].
    Guastavino E; Litwin NH; Heffes Nahmod L; Licastro R
    Acta Gastroenterol Latinoam; 1988; 18(2):107-13. PubMed ID: 2908013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Determination of sulfapyridine levels in serum--a possibility for the control of dose related therapy with sulfasalazine].
    Eitner K; Reinicke C; Hippius M
    Dtsch Z Verdau Stoffwechselkr; 1984; 44(6):282-8. PubMed ID: 6151895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Drug therapy for ulcerative colitis: salazosulfapyridine and 5-ASA].
    Jo Y; Matsumoto T; Iida M
    Nihon Rinsho; 2005 May; 63(5):820-4. PubMed ID: 15881176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of serum concentrations of sulphasalazine and some of its metabolites after therapy by the oral or rectal route.
    Ashworth M; Arthur M; Turmer AD; Smith PR
    Pharmatherapeutica; 1984; 3(8):551-5. PubMed ID: 6142465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative pharmacokinetics of sulphasalazine and sulphapyridine after rectal and oral administration to patients with ulcerative colitis.
    Allgayer H; Kruis W; Eisenburg J; Paumgartner G
    Eur J Clin Pharmacol; 1984; 26(2):275-7. PubMed ID: 6144549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparison of salicylazosulfapyridine bioavailability following oral and rectal administration in patients with ulcerative colitis].
    Sliwiński Z
    Pol Tyg Lek; 1991 Nov 11-25; 46(45-47):879-81. PubMed ID: 1688291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sulfasalazine metabolite pharmacokinetics in pediatric patients with inflammatory bowel disease: effects of disease activity, acetylator phenotype, and age.
    Clarke DF; George D; Milsap RL; Pogonowska-Wala E; Owerbach J; Lebenthal E; Jusko WJ
    Pediatr Pharmacol (New York); 1982; 2(4):323-33. PubMed ID: 6152489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemolysis during salicylazosulfapyridine therapy.
    van Hees PA; van Elferen LW; van Rossum JM; van Tongeren JH
    Am J Gastroenterol; 1978 Nov; 70(5):501-5. PubMed ID: 33552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Estimations of the serum levels of sulfapyridine on patients treated with sulfasalazin (author's transl)].
    Eitner K; Hippius M; Reinicke C
    Dtsch Z Verdau Stoffwechselkr; 1982; 42(1):14-9. PubMed ID: 6122556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between the acetylator phenotype, plasma sulfapyridine levels and adverse effects during treatment with salicylazosulfapyridine in patients with chronic bowel diseases.
    Rahav G; Zylber-Katz E; Rachmilewitz D; Levy M
    Isr J Med Sci; 1990 Jan; 26(1):31-4. PubMed ID: 1968894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Further studies of sulphasalazine metabolism in the treatment of ulcerative colitis.
    Cowan GO; Das KM; Eastwood MA
    Br Med J; 1977 Oct; 2(6094):1057-9. PubMed ID: 21720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of BX661A, a new therapeutic agent for ulcerative colitis, on reactive oxygen species in comparison with salazosulfapyridine and its metabolite sulfapyridine.
    Kimura I; Kumamoto T; Matsuda A; Kataoka M; Kokuba Y
    Arzneimittelforschung; 1998 Oct; 48(10):1007-11. PubMed ID: 9825118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Placental transfer of sulphasalazine and sulphapyridine and some of its metabolites.
    Järnerot G; Into-Malmberg MB; Esbjörner E
    Scand J Gastroenterol; 1981; 16(5):693-7. PubMed ID: 6119765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Sulfasalazine enema in acute left-sided ulcerative colitis (author's transl)].
    Frimberger E; Frühmorgen P; Kühner W; Ottenjann R
    MMW Munch Med Wochenschr; 1980 Sep; 122(36):1233-5. PubMed ID: 6108506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment of steroid refractory active ulcerative colitis with natural interferon-beta--an open long-term trial.
    Musch E; Andus T; Malek M; Chrissafidou A; Schulz M
    Z Gastroenterol; 2007 Dec; 45(12):1235-40. PubMed ID: 18080224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of BX661A, a new therapeutic agent for ulcerative colitis, on chemotaxis and reactive oxygen species production in polymorphonuclear leukocytes in comparison with salazosulfapyridine and its metabolite sulfapyridine.
    Kimura I; Kawasaki M; Matsuda A; Kataoka M; Kokurba Y
    Arzneimittelforschung; 1998 Dec; 48(12):1163-7. PubMed ID: 9893931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicokinetics of sulfasalazine (salicylazosulfapyridine) and its metabolites in B6C3F1 mice.
    Zheng W; Winter SM; Mayersohn M; Bishop JB; Sipes IG
    Drug Metab Dispos; 1993; 21(6):1091-7. PubMed ID: 7905389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of the active moiety of BX661A, a new therapeutic agent for ulcerative colitis, by studying its therapeutic effects on ulcerative colitis induced by dextran sulfate sodium in rats.
    Kimura I; Kawasaki M; Nagahama S; Matsuda A; Kataoka M; Kokuba Y
    Arzneimittelforschung; 1998 Nov; 48(11):1091-6. PubMed ID: 9850431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time course of free and N4-acetylated sulfapyridine concentrations in the plasma and saliva of man after sulfasalazine (salicylazosulfapyridine) administration: preliminary findings.
    Bates TR; Blumenthal HP; Pieniaszek HJ
    Res Commun Chem Pathol Pharmacol; 1976 Sep; 15(1):183-9. PubMed ID: 9675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.